ÂÜÀòÂÒÂ×

Daniel Aleksandrowicz currently serves as Director of Toxicology at Keros Therapeutics, a position held since December 2020. Prior to this, Daniel worked at Epizyme as Associate Director of Nonclinical Safety from July 2017 to December 2020 and managed Toxicology Program and Study Management at Biogen Inc from June 2008 to July 2017. Daniel's earlier experience includes a role as Research Animal Specialist II at Merck from 2005 to 2007, and as an In Vivo Research Technician at Toxikon Corporation from June 2004 to December 2005. Daniel holds a Bachelor of Science degree in Biology from the University of Massachusetts Amherst, completed in 2002.